AbbVie Inc. $ABBV Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 4.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 465,844 shares of the company’s stock after selling 19,684 shares during the quarter. AbbVie comprises approximately 0.3% of Nisa Investment Advisors LLC’s investment portfolio, making the stock its 23rd biggest holding. Nisa Investment Advisors LLC’s holdings in AbbVie were worth $121,860,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Taylor Securities Services Inc. lifted its holdings in shares of AbbVie by 2.6% during the third quarter. Taylor Securities Services Inc. now owns 2,267 shares of the company’s stock worth $593,000 after purchasing an additional 57 shares during the period. Harfst & Associates Inc. boosted its position in AbbVie by 10.2% in the third quarter. Harfst & Associates Inc. now owns 2,855 shares of the company’s stock valued at $747,000 after buying an additional 265 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in AbbVie by 4.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 3,706,187 shares of the company’s stock worth $969,501,000 after buying an additional 141,068 shares during the period. Sensible Money LLC increased its holdings in AbbVie by 24.6% in the 3rd quarter. Sensible Money LLC now owns 1,177 shares of the company’s stock worth $308,000 after buying an additional 232 shares during the period. Finally, Zullo Investment Group Inc. increased its holdings in AbbVie by 1.3% in the 3rd quarter. Zullo Investment Group Inc. now owns 5,613 shares of the company’s stock worth $1,469,000 after buying an additional 71 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 1.5%

Shares of ABBV opened at $284.63 on Thursday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40. The company has a market capitalization of $502.89 billion, a price-to-earnings ratio of 80.41, a PEG ratio of 1.32 and a beta of 0.24. The stock’s 50-day moving average price is $264.93 and its 200-day moving average price is $240.92.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial
• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach
• Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie
• Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment.
• Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Piper Sandler raised their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Canaccord Genuity Group upped their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Argus upped their price objective on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Wells Fargo & Company increased their price objective on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Finally, Citigroup increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.07.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.